



Aug 25, 2020

Financing and Insurance (Part 12 of Phase 3 study of Vaccine Candidate for COVID-19)

In 1 collection

Chris Ockenhouse¹, Chris Gast¹, Renee Holt¹, Jorge Flores¹¹Center for Vaccine Innovation and Access, PATH (Washington D.C. and Seattle, Washington)

1 Works for me dx.doi.org/10.17504/protocols.io.bj59kq96

Coronavirus Method Development Community PATH

Chris Ockenhouse

ABSTRACT

This is Part 12 of "Phase 3 randomized, double-blinded, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of **Vaccine Candidate** against COVID-19 in adults > 18 years of age"

This generic Phase 3 protocol was developed by the PATH team with support of the Bill and Melinda Gates Foundation. The aim of the collection is to share recommended best practices in designing and implementing a Phase 3 study of a COVID-19 vaccine candidate. As Phase 3 trials of different Vaccine Candidates proceed around the world, following the same protocols will ensure consistency and comparability of the Phase 3 trial results.

Please note that this is an evolving document, to be versioned and updated, based on community feedback and new data.

ATTACHMENTS

Generic Phase 3 Protocol
COVID-19 Vaccine-
25AUG2020-version
1.docx

DOI

dx.doi.org/10.17504/protocols.io.bj59kq96

PROTOCOL CITATION

Chris Ockenhouse, Chris Gast, Renee Holt, Jorge Flores 2020. Financing and Insurance (Part 12 of Phase 3 study of Vaccine Candidate for COVID-19). **protocols.io**
<https://dx.doi.org/10.17504/protocols.io.bj59kq96>

COLLECTIONS ⓘ

PATH **Collection of Protocols and Guidelines for Phase 3 study of Vaccine Candidate for COVID-19**

LICENSE

———— This is an open access protocol distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

CREATED

Aug 22, 2020

LAST MODIFIED

Aug 25, 2020

OWNERSHIP HISTORY

Aug 22, 2020  Lenny Teytelman protocols.io

Aug 25, 2020  Chris Ockenhouse

PROTOCOL INTEGER ID

40865

PARENT PROTOCOLS

Part of collection

[Collection of Protocols and Guidelines for Phase 3 study of Vaccine Candidate for COVID-19](#)

GUIDELINES

The trial is supported by funding from **Sponsor** and **XXX**. Funding of the site and CRO activities will also be covered by **XXX**. Pharmaceutical support is provided by **Sponsor**.

Sponsor will secure insurance that complies with the regulatory and legal requirements.